DNA mutation assessments on a subset of tumors to identify any associations with specific KRAS co‐variant subgroups were performed; however, no observed association between NSCLC KRAS co-mutation subgroups and abemaciclib sensitivity or resistance was noted. This evidence concerns the gene KRAS and non-small cell lung carcinoma.